PCA3 medical test as diagnostic intervention for prostate cancer

CVZ has examined whether using the PCA3 gene expression test on patients with suspected prostate cancer and a negative initial series of biopsies as a triage test is effective (clinical utility) for decision-making on whether to carry out a second series of biopsies and whether it thus fulfils the criterion ‘established medical science and medical practice’. There is a lack of direct evidence.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.